Insider · CIK 0001792206
Foresite Capital Management V, LLC
Files at LTGO (Latigo Biotherapeutics, Inc.). First filing Aug 10, 2026, latest Aug 10, 2026.
In brief
Foresite Capital Management V, LLC files SEC Form 4 as 10% owner at LTGO (Latigo Biotherapeutics, Inc.). Since Aug 10, 2026, Foresite Capital Management V, LLC has reported 1 open-market buy worth $2.5M and 0 open-market sells worth $0, the latest filed on Aug 10, 2026.
A track record needs three past buys with six months of prices behind them; Foresite Capital Management V, LLC has 0, so none is measured yet.
The newest scored trade: bought $2.5M of LTGO on Aug 10, 2026, filed Aug 10, 2026, scored 43 (moderate). In the last 12 months: 1 buy worth $2.5M and 0 sells worth $0.
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
LTGO: Latigo Biotherapeutics, Inc.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 43Moderate | Latigo Biotherapeutics, Inc. | $2.5M 140,000 shares | +7% | - |
Transactions
Every row this insider has filed, 15 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Aug 10, 2026 | LTGO Latigo Biotherapeutics, Inc. | CConversion Common Stockindirect: See Footnote | +3,117,664 | $0.00 | $0 | 3,117,664 | Aug 10, 2026 |
| Aug 10, 2026 | LTGO Latigo Biotherapeutics, Inc. | CConversion Common Stockindirect: See Footnote | +445,320 | $0.00 | $0 | 3,562,984 | Aug 10, 2026 |
| Aug 10, 2026 | LTGO Latigo Biotherapeutics, Inc. | CConversion Common Stockindirect: See Footnote | +1,125,823 | $0.00 | $0 | 1,125,823 | Aug 10, 2026 |
| Aug 10, 2026 | LTGO Latigo Biotherapeutics, Inc. | CConversion Common Stockindirect: See Footnote | +742,201 | $0.00 | $0 | 1,868,024 | Aug 10, 2026 |
| Aug 10, 2026 | LTGO Latigo Biotherapeutics, Inc. | POpen-market purchase Common Stockindirect: See Footnote | +140,000 | $18.00 | $2.5M | 2,008,024 | Aug 10, 2026 |
| Aug 10, 2026 | LTGO Latigo Biotherapeutics, Inc. | CConversion Common Stockindirect: See Footnote | +195,776 | - | - | 2,203,800 | Aug 10, 2026 |
| Aug 10, 2026 | LTGO Latigo Biotherapeutics, Inc. | CConversion Common Stockindirect: See Footnote | +3,117,664 | $0.00 | $0 | 3,117,664 | Aug 10, 2026 |
| Aug 10, 2026 | LTGO Latigo Biotherapeutics, Inc. | CConversion Common Stockindirect: See Footnote | +296,880 | $0.00 | $0 | 3,414,544 | Aug 10, 2026 |
| Aug 10, 2026 | LTGO Latigo Biotherapeutics, Inc. | CConversion Series A-2 Convertible Preferred Stockderivativeindirect: See Footnote | -3,117,664 | $0.00 | $0 | 0 | Aug 10, 2026 |
| Aug 10, 2026 | LTGO Latigo Biotherapeutics, Inc. | CConversion Series B Convertible Preferred Stockderivativeindirect: See Footnote | -445,320 | $0.00 | $0 | 0 | Aug 10, 2026 |
| Aug 10, 2026 | LTGO Latigo Biotherapeutics, Inc. | CConversion Series A-2 Convertible Preferred Stockderivativeindirect: See Footnote | -1,125,823 | $0.00 | $0 | 0 | Aug 10, 2026 |
| Aug 10, 2026 | LTGO Latigo Biotherapeutics, Inc. | CConversion Series B Convertible Preferred Stockderivativeindirect: See Footnote | -742,201 | $0.00 | $0 | 0 | Aug 10, 2026 |
| Aug 10, 2026 | LTGO Latigo Biotherapeutics, Inc. | CConversion Series A-2 Convertible Preferred Stockderivativeindirect: See Footnote | -3,117,664 | $0.00 | $0 | 0 | Aug 10, 2026 |
| Aug 10, 2026 | LTGO Latigo Biotherapeutics, Inc. | CConversion Series B Convertible Preferred Stockderivativeindirect: See Footnote | -296,880 | $0.00 | $0 | 0 | Aug 10, 2026 |
| Aug 10, 2026 | LTGO Latigo Biotherapeutics, Inc. | CConversion Convertible Promissory Notederivativeindirect: See Footnote | -195,776 | - | - | 0 | Aug 10, 2026 |
Questions about Foresite Capital Management V, LLC
Answered from the filings on this page, as of the latest one.
Is Foresite Capital Management V, LLC buying or selling?
In the last 12 months Foresite Capital Management V, LLC reported 1 open-market buy worth $2.5M and 0 open-market sells worth $0 on SEC Form 4; the latest was bought $2.5M of LTGO on Aug 10, 2026. Grants, option exercises and tax withholding are not counted.
How did Foresite Capital Management V, LLC's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Foresite Capital Management V, LLC has 0.
Where does Foresite Capital Management V, LLC file Form 4?
Foresite Capital Management V, LLC has filed Form 4 at LTGO (Latigo Biotherapeutics, Inc.). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.